

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Stem Cells

**Manuscript NO:** 67819

**Title:** Treatment of Acute Ischemic Stroke by Minimally Manipulated Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation: A Case Report

**Reviewer's code:** 05937294

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor, Research Assistant Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2021-05-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-05-21 14:03

**Reviewer performed review:** 2021-05-22 13:53

**Review time:** 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

The authors present an interesting study describing the successful management of acute ischemic stroke using intravenous transplantation of minimally manipulated umbilical cord-derived mesenchymal stem cells. There are a few major issues that should be addressed by the authors before consideration for publication: 1. You need to explain more about the mechanism of MSC transplantation in the regeneration of the neurons and brain tissue. 2. Did you recommend the MSCs transplantation during the acute phase of stroke or as a part of rehabilitation? I asked because the aforementioned management was done several weeks after the primary symptoms and also about 2 weeks after initial hospital discharge. 3. Did you recommend the MSCs transplantation in all types of stroke (hemorrhagic or thrombotic)? with any severity regardless of the affected area? 4. You used twice MSCs transplantation in the reported case. Did you follow any guidelines? Or you use did it according to the clinical symptoms or CT scan findings? 5. The following paper is suggested to use in general considerations: • Cell Transplant. 2018 Dec; 27(12):1723-1730. DOI: 10.1177/0963689718806846. Epub 2018 Oct 22. Mesenchymal Stem Cell Therapy in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research. Haiqing Zheng, Bin Zhang, Pratik Y Chhatbar, Yi Dong, Ali Alawieh, Forrest Lowe, Xiquan Hu, Wuwei Feng. 6. You claimed that the reported case is contrary to other studies and didn't develop any presentation such as chills, fever, and nausea. Did you have any suggestions for other physicians around the world to avoid such adverse effects following MSCs transplantation?

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Stem Cells

**Manuscript NO:** 67819

**Title:** Treatment of Acute Ischemic Stroke by Minimally Manipulated Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation: A Case Report

**Reviewer's code:** 02729415

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Academic Fellow, Chief Physician

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2021-05-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-05-23 14:29

**Reviewer performed review:** 2021-05-23 14:33

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

A good case